AU2021366688B2 - Anticancer compounds selective for er-positive cancers - Google Patents

Anticancer compounds selective for er-positive cancers

Info

Publication number
AU2021366688B2
AU2021366688B2 AU2021366688A AU2021366688A AU2021366688B2 AU 2021366688 B2 AU2021366688 B2 AU 2021366688B2 AU 2021366688 A AU2021366688 A AU 2021366688A AU 2021366688 A AU2021366688 A AU 2021366688A AU 2021366688 B2 AU2021366688 B2 AU 2021366688B2
Authority
AU
Australia
Prior art keywords
erso
compound
dfp
trifluoromethyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021366688A
Other languages
English (en)
Other versions
AU2021366688A9 (en
AU2021366688A1 (en
Inventor
Matthew Boudreau
Paul J. Hergenrother
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Illinois System
Original Assignee
University of Illinois at Urbana-Champaign
University of Illinois System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Illinois at Urbana-Champaign, University of Illinois System filed Critical University of Illinois at Urbana-Champaign
Publication of AU2021366688A1 publication Critical patent/AU2021366688A1/en
Publication of AU2021366688A9 publication Critical patent/AU2021366688A9/en
Application granted granted Critical
Publication of AU2021366688B2 publication Critical patent/AU2021366688B2/en
Priority to AU2026204244A priority Critical patent/AU2026204244A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2021366688A 2020-10-23 2021-10-21 Anticancer compounds selective for er-positive cancers Active AU2021366688B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2026204244A AU2026204244A1 (en) 2020-10-23 2026-06-02 Anticancer compounds selective for ER-positive cancers

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063104933P 2020-10-23 2020-10-23
US63/104,933 2020-10-23
PCT/US2021/056003 WO2022087234A1 (en) 2020-10-23 2021-10-21 Anticancer compounds selective for er-positive cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2026204244A Division AU2026204244A1 (en) 2020-10-23 2026-06-02 Anticancer compounds selective for ER-positive cancers

Publications (3)

Publication Number Publication Date
AU2021366688A1 AU2021366688A1 (en) 2023-05-25
AU2021366688A9 AU2021366688A9 (en) 2024-06-20
AU2021366688B2 true AU2021366688B2 (en) 2026-03-05

Family

ID=81290080

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2021366688A Active AU2021366688B2 (en) 2020-10-23 2021-10-21 Anticancer compounds selective for er-positive cancers
AU2026204244A Pending AU2026204244A1 (en) 2020-10-23 2026-06-02 Anticancer compounds selective for ER-positive cancers

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2026204244A Pending AU2026204244A1 (en) 2020-10-23 2026-06-02 Anticancer compounds selective for ER-positive cancers

Country Status (9)

Country Link
US (1) US12655104B2 (enExample)
EP (1) EP4232038A4 (enExample)
JP (1) JP2023546584A (enExample)
CN (1) CN116723841A (enExample)
AU (2) AU2021366688B2 (enExample)
CA (1) CA3196210A1 (enExample)
IL (1) IL302154A (enExample)
MX (1) MX2023004480A (enExample)
WO (1) WO2022087234A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120981469A (zh) * 2023-02-23 2025-11-18 晨晖生物科技(香港)有限公司 含硼化合物及其治疗用途
WO2026039467A1 (en) * 2024-08-12 2026-02-19 The Board Of Trustees Of The University Of Illinois Hydroxyphenyl-indoline-2-one cancer therapeutics

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001098295A1 (fr) * 2000-06-19 2001-12-27 Sanofi-Synthelabo Derives de 1,3-dihydro-2h-indol-2-one et leur utilisation en tant que ligands des recepteurs v1b et v1a de l'arginine-vasopressine
WO2008129075A1 (en) * 2007-04-24 2008-10-30 Topotarget A/S Substituted 3-(4-hydroxyphenyl)-indolin-2-one-compounds
WO2020009958A1 (en) * 2018-07-03 2020-01-09 The Board Of Trustees Of The University Of Illinois Activators of the unfolded protein response

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2855406A (en) 1955-05-07 1958-10-07 Dann Otto Preparation of benzopyrans and benzofurans
US3773759A (en) 1972-08-21 1973-11-20 Searle & Co 1-arylideneamino-4-(2-oxo-3-phenyl-3-benzofuryl)piperazines
EA027139B1 (ru) 2013-04-26 2017-06-30 Бейджин, Лтд. Замещенные 5-(3,5-диметилизоксазол-4-ил)индолин-2-оны
CN108440378B (zh) 2018-03-27 2021-03-12 宁波大学 一种室温下碘-双氧水促进的3-氨基-2-吲哚酮衍生物的制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001098295A1 (fr) * 2000-06-19 2001-12-27 Sanofi-Synthelabo Derives de 1,3-dihydro-2h-indol-2-one et leur utilisation en tant que ligands des recepteurs v1b et v1a de l'arginine-vasopressine
WO2008129075A1 (en) * 2007-04-24 2008-10-30 Topotarget A/S Substituted 3-(4-hydroxyphenyl)-indolin-2-one-compounds
WO2020009958A1 (en) * 2018-07-03 2020-01-09 The Board Of Trustees Of The University Of Illinois Activators of the unfolded protein response

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
GOLDBERG FREDERICK: "A Mild Thermal and Acid-Catalyzed Rearrangement of O-Aryl Ethers into ortho-Hydroxy Arenes", 1 January 2005 (2005-01-01), XP093136490, [retrieved on 20240229] *
LI XIN ET AL: "Chiral Amine Thiourea-Promoted Enantioselective Michael Addition Reactions of 3-Substituted Benzofuran-2(3 H )-ones to Maleimides", THE JOURNAL OF ORGANIC CHEMISTRY, 2010, 75(24): 8697-8700. *
METTE K. CHRISTENSEN ET AL: "Synthesis and Antitumor Effect in Vitro and in Vivo of Substituted 1,3-Dihydroindole-2-ones", JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53(19): 7140-7145. *
N. DI IORIO ET AL: "Michael Addition of Oxindoles to N-(2-tert-Butylphenyl)maleimides: Efficient Desymmetrization for the Synthesis of Atropisomeric Succinimides with Quaternary and Tertiary Stereocenters", SYNTHESIS, 2017, 49(7): 1519-1530 *
NADÈGE DAVID ET AL: "Formal Total Synthesis of Diazonamide A by Indole Oxidative Rearrangement", CHEMISTRY - A EUROPEAN JOURNAL, 2016, 22(31): 10867-10876. *
NICOLAOU K C ET AL: "Chemistry and biology of diazonamide A: first total synthesis and confirmation of the true structure", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2004, 126(40): 12888-12896. *
SHIYAO LIU ET AL: "Chiral Tertiary Sulfonium Salts as Effective Catalysts for Asymmetric Base-Free Neutral Phase-Transfer Reactions", ANGEWANDTE CHEMIE INTERNATIONAL EDITION, 2017, 56(17): 4819-4823. *

Also Published As

Publication number Publication date
AU2021366688A9 (en) 2024-06-20
MX2023004480A (es) 2023-05-04
US12655104B2 (en) 2026-06-16
EP4232038A4 (en) 2024-04-10
IL302154A (en) 2023-06-01
AU2021366688A1 (en) 2023-05-25
JP2023546584A (ja) 2023-11-06
EP4232038A1 (en) 2023-08-30
AU2026204244A1 (en) 2026-06-18
CA3196210A1 (en) 2022-04-28
WO2022087234A1 (en) 2022-04-28
US20230391721A1 (en) 2023-12-07
CN116723841A (zh) 2023-09-08

Similar Documents

Publication Publication Date Title
US8394794B2 (en) Therapeutic compounds
US20250099596A1 (en) Tetrahydronaphthalene compound, and preparation method therefor and use thereof in medicine
JP5694172B2 (ja) カルバゾール化合物および当該化合物の治療用途
KR20220012274A (ko) 플루오린 함유 화합물 및 이의 항암 의학적 용도
TWI837402B (zh) 含氟化合物、含氟化合物之製備方法及其抗癌醫藥用途
JP2022513959A5 (enExample)
JP2021185193A (ja) インデニル化合物、医薬組成物、およびその医学的使用
US20260103470A1 (en) Androgen receptor regulation by small molecule enantiomers
CA3103958A1 (en) Activators of the unfolded protein response
US20230391721A1 (en) Anticancer compounds selective for er-positive cancers
WO2021222738A1 (en) Compounds for estrogen receptor positive cancers
US11274106B2 (en) Topoisomerase inhibitors with antibacterial and anticancer activity
US20250376477A1 (en) Analgesic delta opioid receptor bitopic ligands
US12552806B2 (en) Androgen receptor regulation by small molecule enantiomers
WO2026039467A1 (en) Hydroxyphenyl-indoline-2-one cancer therapeutics
US11731947B2 (en) Deuterated antimicrobial compounds
EA050862B1 (ru) Соединение тетрагидронафталина, и способ его получения, и его применение в медицине
HK40061701A (en) Fluorine-containing compound and anti-cancer medical use thereof
KR20210085427A (ko) Hsp90 억제제로서의 1,2,3-트리아졸 유도체 화합물
PT81096B (en) Process for preparing substituted cinnamyl-2,3-dihydrobenzofuran and analogs useful as anti-inflammatory agents
JPS6299352A (ja) １，１，２−トリフエニル−１−ブテン誘導体

Legal Events

Date Code Title Description
SREP Specification republished
FGA Letters patent sealed or granted (standard patent)